Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: DaVita (DVA), IQVIA Holdings (IQV) and Climb Bio (CLYM)

Tipranks - Tipranks - Thu May 7, 8:44AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on DaVita (DVA), IQVIA Holdings (IQV) and Climb Bio (CLYM).

Claim 55% Off TipRanks

DaVita (DVA)

In a report released today, David S Macdonald from Truist Financial maintained a Hold rating on DaVita. The company’s shares closed last Wednesday at $174.00, close to its 52-week high of $179.60.

According to TipRanks.com, Macdonald is a 5-star analyst with an average return of 10.2% and a 57.9% success rate. Macdonald covers the Healthcare sector, focusing on stocks such as Guardian Pharmacy Services, Inc. Class A, Concentra Group Holdings Parent, Inc., and Ardent Health Partners, Inc. ;'>

Currently, the analyst consensus on DaVita is a Moderate Buy with an average price target of $189.00.

See today’s best-performing stocks on TipRanks >>

IQVIA Holdings (IQV)

In a report released today, Jailendra Singh from Truist Financial reiterated a Buy rating on IQVIA Holdings. The company’s shares closed last Wednesday at $181.93, close to its 52-week low of $176.03.

According to TipRanks.com, Singh has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -13.6% and a 36.7% success rate. Singh covers the Healthcare sector, focusing on stocks such as Hinge Health, Inc. Class A, Fortrea Holdings Inc., and Revolution Medicines. ;'>

IQVIA Holdings has an analyst consensus of Strong Buy, with a price target consensus of $217.11, representing a 34.9% upside. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $213.00 price target.

Climb Bio (CLYM)

In a report released today, Danielle Brill from Truist Financial maintained a Buy rating on Climb Bio. The company’s shares closed last Wednesday at $11.59.

According to TipRanks.com, Brill is a 5-star analyst with an average return of 14.9% and a 52.4% success rate. Brill covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Centessa Pharmaceuticals, and Maze Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Climb Bio with a $19.18 average price target, implying a 97.9% upside from current levels. In a report issued on April 21, TipRanks – Google also upgraded the stock to Buy with a $10.00 price target.

Read More on DVA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).